Aspire Biopharma Holdings, Inc.
ASBPW
NASDAQ Global Market0.02
USD
+0.00
- -
Aspire Biopharma Holdings, Inc.
ASBPW
(NASDAQ Global Market)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Aspire Biopharma Holdings, Inc. Aspire Biopharma Holdings, Inc. (Nasdaq:ASBPW), an early-stage biopharmaceutical company founded in 2021 and headquartered in Estero, Florida, develops and markets disruptive patent-pending technology for novel sublingual delivery mechanisms that enable rapid absorption under the tongue, bypassing the gastrointestinal tract to provide faster treatment impact, higher bioavailability, and high-dose administration with reduced liver impact; core products include Instaprin, a soluble, pH-neutral, fast-acting sublingual high-dose aspirin addressing cardiology emergencies such as suspected acute myocardial infarction, stroke prevention via rapid thromboxane inhibition, and pain management; melatonin sleep-aid; vitamins D, E, and K; testosterone; semaglutide for diabetes and weight management; caffeine-based BUZZ BOMB pre-workout supplement; as well as formulations in development for anti-nausea products, anti-psychotics, erectile dysfunction drugs, seizure medications, and other central nervous system therapies targeting multi-billion-dollar markets in men's health, pain relief, and beyond, primarily in the United States with global partnership outreach. Recent developments include positive final clinical trial results in 2025 demonstrating sublingual aspirin's superior plasma concentrations and twice-as-fast thromboxane inhibition versus chewed aspirin, supporting an H2 2025 FDA submission; a strategic manufacturing partnership with SupraNaturals for initial production of 2 million servings of BUZZ BOMB targeting the $20 billion pre-workout market; expansion of the scientific team with Dr. Mark J. Jaroszeski, PhD, on November 4, 2025, to optimize sublingual technology and extend it across the generic medicines pipeline; 16 formal meetings at CPHI Frankfurt in October 2025 with global pharmaceutical firms including Bayer and Deva Holdings to advance collaborations, licensing, and joint ventures; Nasdaq Global Market listing of common stock and warrants beginning February 20, 2025; and a milestone roadmap through 2026 featuring Phase 1 studies for sublingual ED medication and semaglutide in H1 2026.